Enhancing Safety and Quality of Cardiopulmonary Resuscitation During Coronavirus Pandemic.

Publication date: Jun 11, 2025

Background: Professional knowledge and experience of healthcare organization went through continuous change and development with the progression of COVID-19 pandemic waves. However, carefully developed guidelines for cardiopulmonary resuscitation (CPR) remained largely unchanged regardless of the epidemic situation, with the largest change being a more prominent bioethical approach. It would be possible to further improve the quality of CPR by systematic data collection, the facilitation of prospective studies, and further development of the methodology based on this evidence, as well as by providing information and developing provisions on interventions with expected poor outcomes, and ultimately by refusing resuscitation. Methods: This study involved the critical collection and analysis of literary data originating from the Web of Science and PubMed databases concerning bioethical aspects and the efficacy of CPR during the COVID-19 pandemic. Results: According to the current professional recommendation of the European Resuscitation Council (ERC), CPR should be initiated immediately in case of cardiac arrest in the absence of an exclusionary circumstance. One such circumstance is explicit refusal of CPR by a well-informed patient, which in practice takes the form of a prior declaration. ERC prescribes the following conjunctive conditions for do-not-attempt CPR (DNACPR) declarations: present, real, and applicable. It is recommended to take the declaration as a part of complex end-of-life planning, with the corresponding documentation available in an electronic database. The pandemic has brought significant changes in resuscitation practice at both lay and professional levels as well. Incidence of out-of-hospital resuscitation (OHCA) did not differ compared to the previous period, while cardiac deaths in public places almost halved during the epidemic (p < 0. 001) as did the use of AEDs (p = 0. 037). The number of resuscitations performed by bystanders and by the emergency medical service (EMS) also showed a significant decrease (p = 0. 001), and the most important interventions (defibrillation, first adrenaline time) suffered a significant delay. Secondary survival until hospital discharge thus decreased by 50% during the pandemic period. Conclusions: The COVID-19 pandemic provided a significant impetus to the revision of guidelines. While detailed methodology has changed only slightly compared to the previous procedures, the DNACPR declaration regarding self-determination is mentioned in the context of complex end-of-life planning. The issue of safe environment has come to the fore for both lay and trained resuscitators. Future Directions: Prospective evaluation of standardized methods can further improve the patient's autonomy and quality of life. Since clinical data are controversial, further prospective controlled studies are needed to evaluate the real hazards of aerosol-generating procedures.

Open Access PDF

Concepts Keywords
Arrest cardiac arrest
Cardiac cardiopulmonary resuscitation
Coronavirus coronavirus pandemic
Dnacpr DNACPR order
Healthcare

Semantics

Type Source Name
disease IDO quality
disease MESH COVID-19 pandemic
disease MESH cardiac arrest
disease MESH end-of-life
disease MESH emergency
drug DRUGBANK Epinephrine
drug DRUGBANK Coenzyme M
disease MESH Out of hospital cardiac arrest
disease IDO country
disease MESH complications
disease MESH respiratory failure
disease IDO role
disease MESH sepsis
disease MESH infection
disease IDO intervention
disease IDO disposition
drug DRUGBANK Trestolone
disease IDO process
drug DRUGBANK Etoperidone
disease IDO healthcare facility
drug DRUGBANK Methionine
disease MESH sudden cardiac death
disease MESH hypoxia
disease MESH pulmonary embolism
disease MESH acute coronary syndrome
disease MESH dyspnea
drug DRUGBANK Water
drug DRUGBANK Oxygen
disease MESH functional status
drug DRUGBANK Amiodarone
drug DRUGBANK Lidocaine
disease MESH infection transmission
disease MESH uncertainty
drug DRUGBANK Medical air
drug DRUGBANK Nordazepam
disease MESH shock
disease MESH respiratory infections
drug DRUGBANK Spinosad

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *